Abstract
A reduced-intensity hematopoietic stem cell transplantation (RIST) regimen was developed to induce immunosuppression to facilitate the engraftment of donor cells. However, there have been concerns that the incidence of opportunistic infection may increase after this procedure. To address this problem, we retrospectively analyzed the medical records of 24 RIST recipients who were treated over a recent 16-month period for comparison with 31 recipients of conventional allogeneic transplantation (CST). The RIST regimen consisted of cladribine (0.66 mg/kg), busulfan (8 mg/kg), and rabbit anti-thymocyte globulin (ATG; 5–10 mg/kg). All of the patients received allogeneic peripheral blood stem cells from an HLA-identical or one-locus mismatched related donor. Although the incidence of positive CMV antigenemia was comparable between the two groups (58% vs 68%), RIST patients developed positive antigenemia significantly sooner than did CST patients (P = 0.01) and showed higher initial and maximum antigenemia values (P = 0.026 and P = 0.003, respectively). These findings may suggest that immune recovery against CMV was delayed after our RIST procedure, but this did not directly translate into an increase in clinically significant CMV disease. Early therapeutic intervention with ganciclovir might play a role in preventing the progression of early CMV infection to CMV disease.
Bone Marrow Transplantation (2002) 29, 237–241. doi:10.1038/sj.bmt.1703351
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Giralt S, Estey E, Albitar M et al. Engraftment of allogenic hematopoietic progenitor cells with purine analog containing chemotherapy Blood 1997 89: 4531 4536
Slavin S, Nagler A, Naparstek E et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases Blood 1998 91: 756 763
Khouri IF, Keating M, Korbling M et al. Transplant-lite: induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor cell transplantation as treatment for lymphoid malignancies J Clin Oncol 1998 16: 2817 2824
McSweeney P, Wagner J, Maloney D et al. Outpatient PBSC allografts using immunosuppression with low-dose TBI before, and cyclosporine (CSP) and mycophenolate mofetil (MMF) after transplant Blood 1998 92: (Suppl. 1) 519a (Abstr. 2133)
Childs R, Clave E, Contentin N et al. Reduced toxicity and transplant related mortality (TRM) following non-myeloablative allogeneic peripheral blood stem cell transplantation for malignant diseases Blood 1999 94: 3234 3241
Saito T, Kanda Y, Kanai S et al. Successful non-myeloablative transplant (NST) using a novel combination of cladribine (2-CdA)/busulfan (BU)/ATG: early full donor chimerism but delayed immune reconstitution Blood 2000 96: (Suppl 1) 782a (Abstr. 3380)
Gondo H, Minematsu T, Harada M et al. Cytomegalovirus (CMV) antigenemia for rapid diagnosis and monitoring of CMV-associated disease after bone marrow transplantation Br J Haematol 1994 86: 130 137
Kanda Y, Mineishi S, Saito T et al. Pre-emptive therapy against cytomegalovirus (CMV) diseases guided by CMV antigenemia assay after allogeneic hematopoietic stem cell transplantation: a single-center experience in Japan Bone Marrow Transplant 2001 27: 437 444
Kanda Y, Mineishi S, Saito T et al. Response-oriented pre-emptive therapy against cytomegalovirus diseases with low-dose ganciclovir: a prospective evaluation Transplantation (in press)
Mohty M, Faucher C, Vey N et al. High rate of secondary viral and bacterial infections in patients undergoing allogeneic bone marrow mini-transplantation Bone Marrow Transplant 2000 26: 251 255
Chakrabarti S, Kottaridis P, Ogormon P et al. High incidence of early and late CMV infections and delayed immune reconstitution after allogeneic transplants with nonmyeloablative conditioning using Campath (anti-CD52 antibody) Blood 2000 96: (Suppl.) 586a (Abstr. 2515)
Junghanss C, Boeckh M, Carter R et al. Incidence of herpesvirus infections following nonmyeloablative allogeneic stem cell transplantation Blood 2000 96: (Suppl. 1) 188a (Abstr. 805)
Graber C, de Almeida KNF, Childs R et al. CMV reactivation in nonmyeloablative HSCT Bone Marrow Transplant 2001 27: 775
Trenschel R, Ross S, Husing J et al. Reduced risk of persisting cytomegalovirus pp65 antigenemia and cytomegalovirus interstitial pneumonia following allogeneic PBSCT Bone Marrow Transplant 2000 25: 665 672
Bornhauser M, Thiede C, Schuler U et al. Dose-reduced conditioning for allogeneic blood stem cell transplantation: durable engraftment without antithymocyte globulin Bone Marrow Transplant 2000 26: 119 125
Acknowledgements
This research was supported by a Grant-in-Aid for Scientific Research from the Ministry of Health, Labor and Welfare.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Nakai, K., Kanda, Y., Mineishi, S. et al. Suspected delayed immune recovery against cytomegalovirus after reduced-intensity stem cell transplantation using anti-thymocyte globulin. Bone Marrow Transplant 29, 237–241 (2002). https://doi.org/10.1038/sj.bmt.1703351
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.bmt.1703351
Keywords
This article is cited by
-
Fludarabine-based reduced intensity conditioning transplants have a higher incidence of cytomegalovirus reactivation compared with myeloablative transplants
Bone Marrow Transplantation (2010)
-
A randomized controlled trial of plasma real-time PCR and antigenemia assay for monitoring CMV infection after unrelated BMT
Bone Marrow Transplantation (2010)
-
Rituximab therapy increased post-transplant cytomegalovirus complications in Non-Hodgkin’s lymphoma patients receiving autologous hematopoietic stem cell transplantation
Annals of Hematology (2008)
-
Subcutaneous alemtuzumab vs ATG in adjusted conditioning for allogeneic transplantation: influence of Campath dose on lymphoid recovery, mixed chimerism and survival
Bone Marrow Transplantation (2006)
-
High-grade cytomegalovirus antigenemia after hematopoietic stem cell transplantation
Bone Marrow Transplantation (2005)